We represented Monstanto in a patent infringement matter when the plaintiff patentee, a local public university, alleged that our client’s recombinant bovine growth hormone product infringed its patent and sought $1.8 billion in treble damages and a permanent injunction. After we won a summary judgment eliminating one of the two accused products, and limiting the literal coverage of the claims to technology “known and available” in 1980, the case settled favorably the day before the jury trial was to start.